Global Aspirin Exacerbated Respiratory Disease Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product Type;

Glucocorticoids, Antihistamines, and Aspirin Desensitization

By Route of Administration;

Nasal and Oral

By Distribution Channel;

Hospital Pharmacy, Retail Stores, and Online Pharmacy

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn137376138 Published Date: June, 2025 Updated Date: July, 2025

Aspirin Exacerbated Respiratory Disease Market Overview

Aspirin Exacerbated Respiratory Disease Market (USD Million)

Aspirin Exacerbated Respiratory Disease Market was valued at USD 169.76 million in the year 2024. The size of this market is expected to increase to USD 231.02 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.5%.


Global Aspirin Exacerbated Respiratory Disease Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 4.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.5 %
Market Size (2024)USD 169.76 Million
Market Size (2031)USD 231.02 Million
Market ConcentrationHigh
Report Pages362
169.76
2024
231.02
2031

Major Players

  • Pfizer
  • Teva Pharmaceuticals
  • Cadila
  • Eli Lilly and Company
  • Hindustan Antibiotics Limited
  • Novartis AG
  • Sanofi-aventis Groupe
  • Abbott Laboratories
  • Merck

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Aspirin Exacerbated Respiratory Disease Market

Fragmented - Highly competitive market without dominant players


The Aspirin Exacerbated Respiratory Disease Market is expanding due to the rising burden of respiratory disorders linked to aspirin sensitivity. Nearly 7% of asthma sufferers and 15% of those with chronic rhinosinusitis show AERD symptoms. The growing understanding of this condition is boosting the need for more precise therapeutic strategies that address inflammation and respiratory complications effectively.

Improved Diagnostics Fuel Market Expansion
Advances in diagnostic technologies and clinical protocols have significantly enhanced the early identification of AERD. Around 40% of patients are now diagnosed sooner due to the use of aspirin challenge tests and imaging tools. This trend is leading to an increase in the development of early-intervention treatment plans and furthering the overall growth of the AERD treatment landscape.

Biologic Treatments Transforming Therapeutic Landscape
The use of biologic agents has become a cornerstone in treating moderate to severe AERD cases. Over 30% of patients benefit from therapies such as anti-IL-5 and anti-IgE monoclonal antibodies, which are more effective and better tolerated than traditional drugs. These targeted therapies help reduce nasal polyps, asthma flare-ups, and improve patient quality of life.

Shift Toward Precision Treatment Protocols
The focus on individualized treatment is accelerating across specialized respiratory care centers. Around 50% of treatment regimens are now tailored based on molecular markers and eosinophil counts, improving clinical outcomes and reducing adverse effects. This personalization marks a move toward data-driven, patient-centric care models within the AERD space.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product Type
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Aspirin Exacerbated Respiratory Disease Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Improved Diagnosis Techniques
        2. Growing Awareness
        3. Advancements in Treatment
        4. Rising Healthcare Expenditure
      2. Restraints
        1. Limited Awareness
        2. Adverse Side Effects
        3. Regulatory Challenges
        4. Diagnostic Complexity
      3. Opportunities
        1. Research and Development
        2. Personalized Medicine
        3. Telemedicine Integration
        4. Strategic Collaborations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Aspirin Exacerbated Respiratory Disease Market, By Product Type, 2021 - 2031 (USD Million)
      1. Glucocorticoids
      2. Antihistamines
      3. Aspirin Desensitization
    2. Aspirin Exacerbated Respiratory Disease Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Nasal
      2. Oral
    3. Aspirin Exacerbated Respiratory Disease Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacy
      2. Retail Stores
      3. Online Pharmacy
    4. Aspirin Exacerbated Respiratory Disease Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer
      2. Teva Pharmaceuticals
      3. Cadila
      4. Eli Lilly and Company
      5. Hindustan Antibiotics Limited
      6. Novartis AG
      7. Sanofi-aventis Groupe
      8. Abbott Laboratories
      9. Merck
  7. Analyst View
  8. Future Outlook of the Market